June 12, 2024Open Access

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

Key Points

Key points are not available for this paper at this time.

Abstract

The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy, especially the risk of T-cell neoplasms related to viral vector integration, is an emerging concern.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Hamilton et al. (Wed,) studied this question.

synapsesocial.com/papers/68e64f8fb6db6435875e05cc — DOI: https://doi.org/10.1056/nejmoa2401361

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

EBV+ nodal T/NK-cell lymphoma associated with clonal hematopoiesis and structural variations of the viral genome· 2024 · 15 citations
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma· 2014 · 539 citations
Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging· 2023 · 12 citations
The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma· 2021 · 47 citations
Molecular profiling of EBV associated diffuse large B-cell lymphoma· 2023 · 71 citations

Authors

Mark Hamilton

Takeshi Sugio

Troy Noordenbos

Journals

New England Journal of Medicine

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Also consider